Immunotherapy in anaplastic thyroid cancer: Case series.
증례연속
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: pulmonary metastases received pembrolizumab and lenvatinib
I · Intervention 중재 / 시술
immunotherapy for ATC
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
In conclusion, the treatment responses of immunotherapy, either alone or in combination with other therapies, were highly variable in patients with ATC and should be carefully monitored along with the side effects.
Unresectable anaplastic thyroid cancer (ATC) has a poor prognosis.
APA
Shih SR, Chen KH, et al. (2022). Immunotherapy in anaplastic thyroid cancer: Case series.. Journal of the Formosan Medical Association = Taiwan yi zhi, 121(6), 1167-1173. https://doi.org/10.1016/j.jfma.2022.01.003
MLA
Shih SR, et al.. "Immunotherapy in anaplastic thyroid cancer: Case series.." Journal of the Formosan Medical Association = Taiwan yi zhi, vol. 121, no. 6, 2022, pp. 1167-1173.
PMID
35031200 ↗
Abstract 한글 요약
Unresectable anaplastic thyroid cancer (ATC) has a poor prognosis. Chemotherapy and radiotherapy have limited effects on it. Here, we present four cases who underwent immunotherapy for ATC. The patients were aged between 58 and 70 years. Two male patients with pulmonary metastases received pembrolizumab and lenvatinib. However, they died of septic shock and respiratory failure in 2.7 and 1 months, respectively, after the initiation of combination therapy. Another male patient with stage IVB disease was treated with spartalizumab. The tumor remained stable after surgical debulking but slightly progressed after 23 months. He survived for 45.5 months after spartalizumab initiation. A female patient with BRAF-mutant ATC and lung metastases was treated with a combination of pembrolizumab and lenvatinib, which was complicated with grade 4 transaminitis. The patient subsequently received dabrafenib (a BRAF inhibitor) and trametinib (a MEK inhibitor) treatment, which was continued for 10.2 months with a best response of partial remission. She died 18 months after the initial diagnosis (11.4 months after treatment with dabrafenib and trametinib). In conclusion, the treatment responses of immunotherapy, either alone or in combination with other therapies, were highly variable in patients with ATC and should be carefully monitored along with the side effects.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Aged
- Antibodies
- Monoclonal
- Humanized
- Antineoplastic Combined Chemotherapy Protocols
- Female
- Humans
- Immunotherapy
- Male
- Middle Aged
- Protein Kinase Inhibitors
- Proto-Oncogene Proteins B-raf
- Thyroid Carcinoma
- Anaplastic
- Thyroid Neoplasms
- Anaplastic thyroid cancer
- Immune checkpoint inhibitor
- Targeted therapy
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.